Company Overview of Mallinckrodt LLC
Mallinckrodt LLC manufactures and distributes products used in diagnostic procedures, and in the treatment of pain and related conditions. It offers addiction treatment products, and specialty generics and pharmaceuticals; and active pharmaceutical ingredients, including medicinal narcotics, acetaminophen/paracetamol, stearates, phosphates, and peptides, as well as analytical research samples for pharmaceutical companies and analytical laboratories. The company also supplies medical isotope technetium-99m; and radiopharmaceuticals, and contrast media and delivery systems. It serves customers in the United States and internationally. The company was founded in 1867 and is based in St. Louis, ...
675 McDonnell Boulevard
St. Louis, MO 63042
Founded in 1867
Key Executives for Mallinckrodt LLC
Mallinckrodt LLC does not have any Key Executives recorded.
Mallinckrodt LLC Key Developments
Nuvo Research Inc. Enters into Settlement Agreement with Mallinckrodt Inc
Sep 11 14
Nuvo Research Inc. has entered into a settlement agreement with Mallinckrodt Inc. for a litigation relating to Nuvo's license to Mallinckrodt of the right to market and sell Pennsaid and Pennsaid 2% in the US. Under the terms of the settlement agreement, Mallinckrodt will return all US rights to Pennsaid and Pennsaid 2% to Nuvo after a brief transition period and pay USD 10 million. Pennsaid is used to treat the signs and symptoms associated with knee osteoarthritis (OA). The drug combines the transdermal carrier (containing dimethyl sulfoxide, popularly known as DMSO) with 1.5% diclofenac sodium, a non-steroidal anti-inflammatory drug (NSAID) and delivers the active drug through the skin directly to the site of inflammation and pain. Pennsaid is currently marketed in the US by Mallinckrodt, in Canada by Paladin Labs Inc. and marketed under license and/or distribution agreements in Greece, Italy and the UK.
IGI, Laboratories, Inc. Enters into Non-Exclusive License with Mallinckrodt LLC and Nuvo Research Inc
Jun 26 14
IGI Laboratories Inc. announced that it has entered into an agreement with Mallinckrodt LLC, Mallinckrodt Inc., and Nuvo Research Inc. to settle a declaratory judgment action brought by IGI, concerning IGI's filing of an abbreviated new drug application with the U.S. Food and Drug Administration seeking approval to market a generic version of PENNSAID (diclofenac sodium topical solution) 1.5% w/w. Under the terms of this agreement, Mallinckrodt granted IGI a non-exclusive license to launch its diclofenac sodium topical solution 1.5% product on March 28, 2015. IGI received tentative approval of its diclofenac sodium topical solution 1.5% from the FDA on May 7, 2014.
Mallinckrodt Pharmaceuticals Presents at ChinaBio(R) Partnering Forum 2014, May-07-2014 04:45 PM
May 1 14
Mallinckrodt Pharmaceuticals Presents at ChinaBio(R) Partnering Forum 2014, May-07-2014 04:45 PM. Venue: Kempinski Hotel Suzhou, Suzhou, China.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|